Context Therapeutics Inc. Files 8-K on Shareholder Votes

TL;DR

CTX shares: 8-K filed, shareholder votes on the table. Watch for updates.

AI Summary

Context Therapeutics Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the company's corporate structure, including its former name 'Context Therapeutics LLC' which changed on January 28, 2021. The company is incorporated in Delaware and its principal executive offices are located in Philadelphia, Pennsylvania.

Why It Matters

This filing indicates that Context Therapeutics Inc. is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding shareholder votes and does not immediately indicate significant financial or operational risks.

Key Numbers

• 001-40654 — SEC File Number (Identifies the company's filing with the SEC.)
• 86-3738787 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Context Therapeutics Inc. (company) — Registrant
• Context Therapeutics LLC (company) — Former company name
• 2001 Market Street, Suite 3915 , Unit #15 Philadelphia , Pennsylvania 19103 (location) — Principal executive offices address
• 267-225-7416 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check

Filing Documents

• cntx-20240613.htm (8-K) — 35KB
• 0001842952-24-000041.txt ( ) — 168KB
• cntx-20240613.xsd (EX-101.SCH) — 2KB
• cntx-20240613_lab.xml (EX-101.LAB) — 24KB
• cntx-20240613_pre.xml (EX-101.PRE) — 14KB
• cntx-20240613_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 13, 2024, Context Therapeutics Inc. (the "Company") held its Annual Meeting of Stockholders. As of April 15, 2024, the record date for the Annual Meeting, there were 15,966,053 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 8,486,458, or 53.15%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held and cumulative voting for directors is not permitted. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting. Proposal 1. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The voting on this proposal is set forth below: For Against Abstentions Broker Non-Votes Ratification of CohnReznick LLP 8,364,879 117,835 3,744 --- Proposal 2. Election of Directors The Company's stockholders elected the following director nominees to the Company's Board of Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified. For Withheld Broker Non-Votes Richard Berman 4,774,152 1,873,694 1,838,612 Dr. Philip Kantoff 6,047,097 600,749 1,838,612 Martin Lehr 6,637,406 10,440 1,838,612 Jennifer Evans Stacey 5,028,962 1,618,884 1,838,612 Linda West 6,063,962 583,884 1,838,612

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 14, 2024 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR